Form 8-K

8-K — BRAINSTORM CELL THERAPEUTICS INC.

Accession: 0001104659-26-037760

Filed: 2026-03-31

Period: 2026-03-31

CIK: 0001137883

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2610751d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2610751d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2610751d1_8k.htm · Sequence: 1

false

0001137883

2026-03-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 31, 2026

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-36641

20-7273918

(State or other jurisdiction of

incorporation)

(Commission File No.)

(IRS Employer Identification No.)

1325 Avenue of Americas, 28th Floor

New York, NY

10019

(Address of principal executive offices)

(Zip Code)

(201) 488-0460

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed

since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00005 par value

BCLI

OTCQB Venture Market

(OTCQB)

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the

registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On March 31, 2026, Brainstorm Cell Therapeutics

Inc. issued a press release announcing its financial results for the year ended December 31, 2025. The full text of the press release

is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including

Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in

such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release issued by Brainstorm Cell Therapeutics Inc. on March 31, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

BRAINSTORM CELL THERAPEUTICS INC.

Date: March 31, 2026

By:

/s/ Chaim Lebovits

Chaim Lebovits

President and Co-Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2610751d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

BrainStorm Cell Therapeutics Announces Full

Year 2025 Financial Results and Provides Corporate Update

Strategic $2.0 million post year-end financing

and re-rating of BCLI shares underscore market confidence

Company highlights durable long-term survival in

Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria

NEW YORK, March 31, 2026 /PRNewswire/

-- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases,

today announced financial results for the full year ended December 31, 2025, and provided a corporate update.

“Our main priority continues to be advancing

NurOwn into a Phase 3b confirmatory study, having received clearance from the FDA in 2025 for the planned study,” said Chaim Lebovits,

President and CEO. “This study is designed to generate confirmatory data to support a potential BLA submission. Having completed

key regulatory steps, the SPA, CMC alignment, and the May 2025 FDA clearance, we believe we have addressed some of the primary hurdles

in our development program and positioned the company for success. Our network of leading clinical sites are on standby, and we remain

actively engaged with regulators. Further, we believe that the $2.0 million in strategic financing secured in early 2026 has served as

the catalyst for our recovery, resulting in a significant re-rating of our shares and providing the cash runway to execute on key operational

activities. ALS is a devastating disease with limited treatment options, and we remain committed to the ALS community as we work to complete

development of NurOwn and make it available to patients.”

Recent Highlights

NurOwn (MSC-NTF) for ALS

· Company continues to execute on operational,

clinical and manufacturing activities to support the Phase 3b ENDURANCE study of NurOwn. The planned study is expected to enroll approximately

200 participants at leading ALS centers and is designed as a two-part trial consisting of a 24-week randomized, double-blind, placebo-controlled

portion (Part A), followed by a 24-week open-label extension (Part B) to further assess long-term safety and durability of effect.

The primary efficacy endpoint for Part A will be change from baseline to Week 24 on the ALSFRS-R. If successful, the Company believes

these data could support a potential BLA submission. Further trial details are posted on ClinicalTrials.gov ID NCT06973629.

· A Citizen Petition was filed with the FDA

by representatives of the ALS community. The petition requests a renewed regulatory review of the data supporting NurOwn. BrainStorm

acknowledges the petition as a constructive development that underscores the continued interest in NurOwn's potential therapeutic value.

The Company did not participate in the drafting or submission of this petition.

· In the Expanded Access Program (EAP), 50%

of patients (5/10) remain alive according to publicly available data. Estimated mean survival has reached approximately 84 months.

At the time of the Citizen Petition filing (July 2025), all five surviving patients were tracheostomy-free, as documented in the

petition. All 10 EAP patients exceeded 5-year survival versus ~20% historically. Notably, these patients entered into the Phase 3 trial

with higher baseline function (mean ALSFRS-R of approximately 41), reinforcing the strategic focus of the Phase 3b trial on earlier-stage

populations where the treatment effect may be most detectable.

Corporate

· In February 2026, the company entered into

two strategic private placement agreements, each consisting of stock and warrants, securing a total of $2 million in funding. Together,

the company hopes these financings will reinforce a stable valuation for the company and provide the resources to support near-term operational

objectives and preparatory work for the planned Phase 3b ENDURANCE trial of NurOwn.

Financial Results for the full year Ended December 31, 2025

· Cash, cash equivalents, and restricted cash were

approximately $0.3 million as of December 31, 2025. Subsequent to year-end, the company secured an additional $2 million in funding

through two private placements, as described above.

· Research and development expenditures, net, for

the year ended December 31, 2025 were $4.2 million, compared to $4.7 million for the year ended December 31,

2024.

· General and administrative expenses for the twelve

months ended December 31, 2025, and 2024 were approximately $5.8 million and $7.0 million, respectively.

· Net loss for the twelve months ended December 31,

2025, was approximately $10.3 million, as compared to a net loss of approximately $11.6 million for the twelve months ended December 31,

2024.

· Net loss per share for the twelve months ended December 31,

2025, and 2024 was $1.11 and $2.31, respectively.

About NurOwn®

The NurOwn® technology platform (autologous

MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative

disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated

ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels

of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines

directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics

Inc.

BrainStorm

Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative

diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic

factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

NurOwn® is BrainStorm’s lead investigational

therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is

set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights

into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal

time points, and a comprehensive analysis of the “Floor Effect” — a critical challenge in measuring clinical outcomes

in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed

a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from

the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic

proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational

patent covering its exosome technology, further strengthening BrainStorm’s growing IP portfolio in this emerging area of regenerative

medicine. To learn more, visit www.brainstorm-cell.com.

Notice Regarding Forward-Looking Statements

This

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements

regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn

as a therapy for the treatment of ALS, the future availability of NurOwn to patients, the Phase 3b ENDURANCE study of NurOwn and the

future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking

statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate,"

"believe," "contemplate," "could," "estimate," "expect," "intend," "seek,"

"may," "might," "plan," "potential," "predict," "project," "target,"

"aim," "should," "will" "would," or the negative of these words or other similar expressions,

although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations

and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties

include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital,

BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future

interactions with the FDA will have productive outcomes, whether Brainstorm can successfully fund and complete the Phase 3b ENDURANCE

study of NurOwn and other factors detailed in BrainStorm's annual report on Form 10-K available at http://www.sec.gov. These factors

should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking

statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this

press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances

or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations

reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investors:

Michael Wood

Phone: +1 646-597-6983

mwood@lifesciadvisors.com

Media:

Uri Yablonka, Chief Business Officer

Phone: +1 917-284-2911

uri@brainstorm-cell.com

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

(Except share data)

December 31,

2025

2024

U.S. $ in thousands

ASSETS

Current Assets:

Cash and cash equivalents

$ 29

$ 187

Other accounts receivable

Prepaid expenses and other current assets

192

135

Total current assets

$ 307

$ 385

Long-Term Assets:

Other long-term assets

$ 25

$ 22

Restricted Cash

247

184

Operating lease right of use asset (Note 4)

208

807

Property and Equipment, Net (Note 5)

235

434

Total Long-Term Assets

$ 715

$ 1,447

Total assets

$ 1,022

$ 1,832

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current Liabilities:

Accounts payables

$ 7,067

$ 6,080

Accrued expenses

396

619

Short-term loans (Note 11)

967

300

Operating lease liability (Note 4)

208

549

Employees related liability

2,369

1,430

Total current liabilities

$ 11,007

$ 8,978

Long-Term Liabilities:

Operating lease liability (Note 4)

—

171

Warrants liability (Note 7)

—

447

Total long-term liabilities

$ —

$ 618

Total liabilities

$ 11,007

$ 9,596

Stockholders’ Deficit:

Stock capital: (Note 8)

Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at December 31, 2025 and 100,000,000 shares at December 31, 2024 respectively; Issued and outstanding: 11,034,775 and 6,141,762 shares at December 31, 2025 and December 31, 2024 respectively

Additional paid-in-capital

227,058

218,974

Treasury stocks

(116 )

Accumulated deficit

(236,943 )

(226,636 )

Total stockholders’ deficit

$ (9,985 )

$ (7,764 )

Total liabilities and stockholders’ deficit

$ 1,022

$ 1,832

The accompanying notes are an integral part of the consolidated financial

statements.

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE

LOSS

U.S. dollars in thousands

(Except share data)

Year ended

December 31,

2025

2024

U.S. $ in thousands

Operating expenses:

Research and development

$ 4,175

$ 4,651

General and administrative

5,778

7,042

Operating loss

(9,953 )

(11,693 )

Financial expense, net

533

Gain on change in fair value of Warrants liability (Note 7)

179

147

Net loss

$ (10,307 )

$ (11,623 )

Basic and diluted net loss per share

$ (1.11 )

$ (2.31 )

Weighted average number of shares outstanding used in computing basic and diluted net loss per share

9,268,976

5,021,798

The accompanying notes are an integral part of the

consolidated financial statements.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Mar. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 31, 2026

Entity File Number

001-36641

Entity Registrant Name

Brainstorm Cell Therapeutics Inc.

Entity Central Index Key

0001137883

Entity Tax Identification Number

20-7273918

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1325 Avenue of Americas

Entity Address, Address Line Two

28th Floor

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10019

City Area Code

201

Local Phone Number

488-0460

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.00005 par value

Trading Symbol

BCLI

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration